Clinical Trial Update: Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial (ULTIMUS-1) evaluating NP-G2-044 (Prilukae) with PLD for platinum-resistant ovarian cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• NP-G2-044 (Prilukae) (NP-G2-044)
• PLD (pegylated liposomal doxorubicin)

Snippet

Sponsor: Novita Pharmaceuticals, Inc. | Conditions: Platinum-resistant Ovarian Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING